Tearlab Corp. buy melinda
Start price
12.07.16
/
50%
€7.43
Target price
28.07.16
€7.67
Performance (%)
4.47%
End price
28.07.16
€7.76
Summary
This prediction ended on 28.07.16 with a price of €7.76. With a performance of 4.47%, the BUY prediction by melinda for Tearlab Corp. closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Tearlab Corp. | - | - | - | - |
| iShares Core DAX® | -1.338% | -5.619% | 3.378% | 51.204% |
| iShares Nasdaq 100 | -1.067% | 2.598% | 19.132% | 93.733% |
| iShares Nikkei 225® | -1.991% | -6.512% | 27.854% | 51.187% |
| iShares S&P 500 | -1.316% | 0.905% | 14.189% | 65.291% |
Comments by melinda for this prediction
In the thread Tearlab Corp. diskutieren
folgen
| Quelle: TearLab Gesellschaft
SAN DIEGO, die 12. Juli 2016 (GLOBE NEWSWIRE) - TearLab Corporation (NASDAQ), ein Unternehmen , das und vertreibt ophthalmologische Point of Care in - vitro - Diagnostik entwickelt, heute anerkannt Shire plc bei der kürzlich erteilten Genehmigung US Food and Drug Administration (FDA) Xiidra ™ ( lifitegrast ophthalmische Lösung) 5% für die Behandlung von Anzeichen und Symptomen des trockenen Auges (DED).